We report a selective ruthenium catalyzed reduction of tertiary amides on the side chain of Fmoc-Gln-OtBu derivatives, leading to innovative unnatural α,β or γ-amino acids functionalized with tertiary amines. Rapid and scalable, this process allowed us to build a library of basic unnatural aminoacids at the gram-scale and directly usable for liquid- or solid-phase peptide synthesis. The diversity
我们报道了选择性钌催化的Fmoc-Gln-O t Bu衍生物侧链上的叔酰胺还原,导致创新的用叔胺官能化的非天然α,β或γ-氨基酸。快速且可扩展,该过程使我们能够建立克级的基本非天然氨基酸文库,并可直接用于液相或固相肽合成。可用叔胺的多样性使我们能够调节所得氨基酸的物理化学性质,例如碱性或疏水性。
Amino-oxetanes as amide isosteres by an alternative defluorosulfonylative coupling of sulfonyl fluorides
作者:Juan J. Rojas、Rosemary A. Croft、Alistair J. Sterling、Edward L. Briggs、Daniele Antermite、Daniel C. Schmitt、Luka Blagojevic、Peter Haycock、Andrew J. P. White、Fernanda Duarte、Chulho Choi、James J. Mousseau、James A. Bull
DOI:10.1038/s41557-021-00856-2
日期:2022.2
This disconnection, comparable to a typical amidation, will allow the application of vast existing amine libraries. The reaction is tolerant to a wide range of polar functionalities and is suitable for array formats. Ten oxetane analogues of bioactive benzamides and marketed drugs are prepared. Kinetic and computational studies support the formation of an oxetane carbocation as the rate-determining
[DE] NEUE 2,5-DISUBSTITUIERTE PYRIMIDINDERIVATE<br/>[EN] NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE PYRIMIDINE 2,5-DISUBSTITUES
申请人:BAYER HEALTHCARE AG
公开号:WO2004009589A1
公开(公告)日:2004-01-29
Die vorliegende Erfindung betrifft neue 2,5-disubstituierte Pyrimidin-Derivate, welche die lösliche Guanylatcyclase stimulieren, Verfahren zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln, insbesondere von Arzneimittel zur Behandlung von Krankheiten des Zentralnervensystems.
[EN] GLYT1 TRANSPORTER INHIBITORS<br/>[FR] INHIBITEURS DU TRANSPORTEUR GLYT1
申请人:GLAXO GROUP LTD
公开号:WO2005049023A1
公开(公告)日:2005-06-02
The invention provides a compound of formula (I): or a salt, solvate or a physiologically functional derivative thereof, wherein R1 to R10 are as defined in the specification and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.
[EN] 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE-1<br/>[FR] SULFONYL-AZABICYCLO[3.2.1]OCTANES SUBSTITUÉS EN POSITION 6 UTILES POUR INHIBER LA 11B-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
申请人:SCHERING CORP
公开号:WO2009023181A1
公开(公告)日:2009-02-19
In its many embodiments, the present invention relates to a novel class of 6-substituted sulfonyl-1,3,3-trialkyl-6-azabicyclo[3.2.1]octane compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.